DUBLIN, Mar 13, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "The Top 250 Developers of In-Vitro Diagnostics Tests for Cancer, Cardiovascular & Infectious Diseases" report to their offering.

Did you know?

- Daniella Cramp is Global President, Cardiometabolic at Alere Inc..

- Beijing Wantai Biological Pharmacy's Beijing plant is the largest manufacturing base for the production of infectious diseases diagnostics in China.

- MDxHealth was the winner of the 2016 Frost & Sullivan Global Prostate Cancer Diagnostics Technology Innovation Award.

- iTP Biomedica Corp., the Canadian developer of diagnostic tools for cancers, is oriented to collaborative co-diagnostics development.

- Arbor Vita Corporation's flagship product - the OncoE6 Cervical Test - has proven to be the most accurate test available worldwide for detecting cervical cancer. It is the only cervical cancer test that provides real-time results at the point-of-care.

- Response Biomedical Corp., a global leader in cardiovascular point-of-care testing, has a wide range of markers available on its RAMP® platform including Troponin I, CK-MB, Myoglobin, NT-proBNP and D-dimer.

- On May 25, 2016, Philips Handheld Diagnostics announced the launch of a new handheld blood test, the minicare I-20 system, for rapid diagnosis (Less than 10 minutes) of a heart attack at the point-of-care.

- On February 1, 2017, Great Basin Scientific, Inc. announced the completion of the clinical trial and 510(k) submission to the FDA of its Bordetella Direct Test.

- Meridian Bioscience, Inc. reported full-year fiscal 2016 net revenues of $196.1 million.

- In July, 2016, the Swiss-based global biopharmaceutical group, Debiopharm Group, acquired a majority holding in GenePOC, Inc., the Canadian developer of affordable, simple, and rapid point-of-care molecular diagnostic tests for infectious diseases.

This unique and comprehensive report (438 pages) identifies and profiles the leading 250 developers of in-vitro diagnostics tests for cancer, cardiovascular and infectious diseases. They are located right across the globe from the United States and Europe to India and China.

Report Target Market:

1) In-Vitro Diagnostics Companies

Usage: competitive/financial analysis and strategic partner/alliance identification.

2) Suppliers

The Top 250 Developers Of In-Vitro Diagnostics Tests For Cancer, Cardiovascular & Infectious Diseases' is perfect for suppliers of raw materials, technology and services to identify top potential customers.

3) Distributors

This report is ideal for distributors of in-vitro diagnostics instruments and tests to identify the leading manufacturers with the best products.

4) Industry Associations:

The Top 250 Developers Of In-Vitro Diagnostics Tests For Cancer, Cardiovascular & Infectious Diseases' is a useful reference tool for in-vitro diagnostic associations.

Report data field structure is as follows:

- Company Name

- Address

- Telephone

- Fax

- Email

- Website

- Year Established

- Number of Employees

- Key Executives

- Company Description

- Products

- Clinical Specialties

- Revenue ($U.S. million)

- Location Status

- Ownership

- Stock Exchange/Ticker Symbol

- Parent Company

For more information about this report visit http://www.researchandmarkets.com/research/v6w6th/the_top_250

Media Contact:

Research and Markets

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com

SOURCE Research and Markets